# Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab

> **NCT01123356** · PHASE2 · COMPLETED · sponsor: **Medical University of South Carolina** · enrollment: 21 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Ofatumumab
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01123356
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2013-05
- **Final completion:** 2013-06
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2015-12-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01123356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01123356, "Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01123356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*